Human Microbiome Market Size, Share, and Analysis, By Product (Drugs, Diagnostic Tests, Probiotics, Prebiotics, Others), By Application (Therapeutics and Diagnostics), By Disease (Infectious Disease, Gastrointestinal Disease, Endocrine & Metabolic Disorders, Cancer, Others Diseases) By Type (FMT, Peptide, Live Biotherapeutic Product, and Others), By End-User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Food Businesses, Others) By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034
Human Microbiome Market Size, Share, and Analysis, By Product (Drugs, Diagnostic Tests, Probiotics, Prebiotics, Others), By Application (Therapeutics and Diagnostics), By Disease (Infectious Disease, Gastrointestinal Disease, Endocrine & Metabolic Disorders, Cancer, Others Diseases) By Type (FMT, Peptide, Live Biotherapeutic Product, and Others), By End-User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Food Businesses, Others) By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034
PRODUCT OVERVIEW
Human Microbiome Market is projected to exhibit a Compound Annual Growth Rate (CAGR) of 22.9% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 0.4 billion and is projected to reach USD 3.8 billion by the completion of 2034.
Human Microbiome refers to the vast collection of microorganisms, including bacteria, viruses, fungi, and other microbes, that reside on and inside the human body. These microorganisms inhabit various sites such as the skin, mouth, gut, and other mucosal surfaces. The gut microbiome, in particular, is the most studied and contains trillions of microbes that play crucial roles in digestion, immune function, and overall health. The microbiome is dynamic and influenced by factors like diet, lifestyle, environment, and antibiotics. It contributes to the development and regulation of the immune system, protects against pathogens, and helps in synthesizing essential nutrients and vitamins. Research into the human microbiome aims to harness its potential for therapeutic interventions and personalized medicine.
MARKET HIGHLIGHTS
Human Microbiome Market is expected to reach USD 3.8 billion during the forecast period, due to increasing research, technological advancements, and rising awareness of the microbiome's role in health and disease. Key highlights include the expansion of microbiome-based therapies, diagnostics, and probiotics, with substantial investments from pharmaceutical companies and venture capitalists. The market encompasses a wide range of applications, including gastrointestinal health, metabolic disorders, immune regulation, and mental health. A high phase in the market is the development of microbiome therapeutics, particularly fecal microbiota transplantation (FMT) and microbiome-modulating drugs. The human microbiome market holds immense potential. Continued research and collaboration among scientists, clinicians, and industry stakeholders are essential to overcoming these obstacles and fully realizing the therapeutic and diagnostic potential of the human microbiome, ultimately leading to innovative healthcare solutions and personalized medicine approaches.
Human Microbiome Market Segments:
Growth Drivers
Technological Advancements in Microbiome Research is Expected to Foster Market Expansion
Rising Incidence of Chronic Diseases drives the demand for innovative microbiome-based therapies and interventions as potential treatments.
Restraint
Limited public awareness and education Can Limit the Growth of the Human Microbiome Market
Key Players
PRODUCT OVERVIEW
Human Microbiome Market is projected to exhibit a Compound Annual Growth Rate (CAGR) of 22.9% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 0.4 billion and is projected to reach USD 3.8 billion by the completion of 2034.
Human Microbiome refers to the vast collection of microorganisms, including bacteria, viruses, fungi, and other microbes, that reside on and inside the human body. These microorganisms inhabit various sites such as the skin, mouth, gut, and other mucosal surfaces. The gut microbiome, in particular, is the most studied and contains trillions of microbes that play crucial roles in digestion, immune function, and overall health. The microbiome is dynamic and influenced by factors like diet, lifestyle, environment, and antibiotics. It contributes to the development and regulation of the immune system, protects against pathogens, and helps in synthesizing essential nutrients and vitamins. Research into the human microbiome aims to harness its potential for therapeutic interventions and personalized medicine.
MARKET HIGHLIGHTS
Human Microbiome Market is expected to reach USD 3.8 billion during the forecast period, due to increasing research, technological advancements, and rising awareness of the microbiome's role in health and disease. Key highlights include the expansion of microbiome-based therapies, diagnostics, and probiotics, with substantial investments from pharmaceutical companies and venture capitalists. The market encompasses a wide range of applications, including gastrointestinal health, metabolic disorders, immune regulation, and mental health. A high phase in the market is the development of microbiome therapeutics, particularly fecal microbiota transplantation (FMT) and microbiome-modulating drugs. The human microbiome market holds immense potential. Continued research and collaboration among scientists, clinicians, and industry stakeholders are essential to overcoming these obstacles and fully realizing the therapeutic and diagnostic potential of the human microbiome, ultimately leading to innovative healthcare solutions and personalized medicine approaches.
Human Microbiome Market Segments:
- By Product
- Drugs
- Diagnostic Tests
- Probiotics
- Prebiotics
- Others
- By Application
- Therapeutics
- Diagnostics
- Others
- By Disease
- Infectious Disease
- Gastrointestinal Disease
- Endocrine & Metabolic Disorders
- Cancer
- Others Diseases
- By Type
- FMT
- Peptide
- Live Biotherapeutic Product
- Others
- By End-User
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Food Businesses
- Others
Growth Drivers
Technological Advancements in Microbiome Research is Expected to Foster Market Expansion
Rising Incidence of Chronic Diseases drives the demand for innovative microbiome-based therapies and interventions as potential treatments.
Restraint
Limited public awareness and education Can Limit the Growth of the Human Microbiome Market
Key Players
- Vedanta Biosciences
- Seres Therapeutics
- Second Genome
- Rebiotix
- Microbiome Insights
- 4D Pharma
- Synlogic
- Microbiome Therapeutics
- AOBiome
- uBiome
- Finch Therapeutics
- Seed Health
- Viome
- Holobiome
- Axial Biotherapeutics
- Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)
- North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAG.R – United States and Canada
- Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
- Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
- Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
- Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 3-month post-sales analyst support.
1.EXECUTIVE SUMMARY
1.1. Regional Market Share
1.2.Business Trends
1.3. Human Microbiome Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. RESEARCH METHODOLOGY
2.1.Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4.Primary Research
2.5.Secondary Research
2.5.1.Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. MARKET CHARACTERISTICS
3.1.Market Definition
3.2.Human Microbiome Market: COVID-19 Impact
3.3. Key Segmentations
3.4.Key Developments
3.5.Allied Industry Data
4.HUMAN MICROBIOME MARKET – INDUSTRY INSIGHTS
4.1. Industry Segmentation
4.2.COVID-19 overview of world economy
4.3.Industry Ecosystem Channel Analysis
4.4.Innovation & Sustainability
5. MACROECONOMIC INDICATORS
6. RECENT DEVELOPMENTS
7. MARKET DYNAMICS
7.1.Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4.Market Restraints
7.5. Market Trends
8.RISK ANALYSIS
9. MARKET ANALYSIS
9.1.Porter's Five Forces
9.2. PEST Analysis
9.2.1.Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10.HUMAN MICROBIOME MARKET
10.1.Overview
10.2. Historical Analysis (2018-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. HUMAN MICROBIOME MARKET SIZE & FORECAST 2024A-2034F
11.1. Overview
11.2.Key Findings
11.3.Market Segmentation
11.3.1.By Product
11.3.1.1. Drugs
11.3.1.1.1.By Value (USD Million) 2024A-2034F
11.3.1.1.2. Market Share (%) 2024A-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.1.2.Diagnostic Tests
11.3.1.2.1. By Value (USD Million) 2024A-2034F
11.3.1.2.2.Market Share (%) 2024A-2034F
11.3.1.2.3.Y-o-Y Growth (%) 2024A-2034F
11.3.1.3.Probiotics
11.3.1.3.1. By Value (USD Million) 2024A-2034F
11.3.1.3.2.Market Share (%) 2024A-2034F
11.3.1.3.3.Y-o-Y Growth (%) 2024A-2034F
11.3.1.4.Prebiotics
11.3.1.4.1. By Value (USD Million) 2024A-2034F
11.3.1.4.2.Market Share (%) 2024A-2034F
11.3.1.4.3.Y-o-Y Growth (%) 2024A-2034F
11.3.1.5.Others
11.3.1.5.1. By Value (USD Million) 2024A-2034F
11.3.1.5.2.Market Share (%) 2024A-2034F
11.3.1.5.3.Y-o-Y Growth (%) 2024A-2034F
11.3.2. By Application
11.3.2.1.Therapeutics
11.3.2.1.1. By Value (USD Million) 2024A-2034F
11.3.2.1.2.Market Share (%) 2024A-2034F
11.3.2.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.2.2. Diagnostics
11.3.2.2.1.By Value (USD Million) 2024A-2034F
11.3.2.2.2. Market Share (%) 2024A-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2.3. Others
11.3.2.3.1.By Value (USD Million) 2024A-2034F
11.3.2.3.2. Market Share (%) 2024A-2034F
11.3.2.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.By Disease
11.3.3.1.Infectious Disease
11.3.3.1.1. By Value (USD Million) 2024A-2034F
11.3.3.1.2.Market Share (%) 2024A-2034F
11.3.3.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.3.2. Gastrointestinal Disease
11.3.3.2.1.By Value (USD Million) 2024A-2034F
11.3.3.2.2. Market Share (%) 2024A-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.3. Endocrine & Metabolic Disorders
11.3.3.3.1.By Value (USD Million) 2024A-2034F
11.3.3.3.2. Market Share (%) 2024A-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.4. Cancer
11.3.3.4.1.By Value (USD Million) 2024A-2034F
11.3.3.4.2. Market Share (%) 2024A-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.5. Others Diseases
11.3.3.5.1.By Value (USD Million) 2024A-2034F
11.3.3.5.2. Market Share (%) 2024A-2034F
11.3.3.5.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.By Type
11.3.4.1.Fecal Microbiota Transplantation (FMT)
11.3.4.1.1. By Value (USD Million) 2024A-2034F
11.3.4.1.2.Market Share (%) 2024A-2034F
11.3.4.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.4.2. Peptide
11.3.4.2.1.By Value (USD Million) 2024A-2034F
11.3.4.2.2. Market Share (%) 2024A-2034F
11.3.4.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.3. Live Biotherapeutic Product
11.3.4.3.1.By Value (USD Million) 2024A-2034F
11.3.4.3.2. Market Share (%) 2024A-2034F
11.3.4.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.4.Others
11.3.4.4.1.By Value (USD Million) 2024A-2034F
11.3.4.4.2. Market Share (%) 2024A-2034F
11.3.4.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.5.By End-Users
11.3.5.1.Hospitals & Clinics
11.3.5.1.1. By Value (USD Million) 2024A-2034F
11.3.5.1.2.Market Share (%) 2024A-2034F
11.3.5.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.5.2. Pharmaceutical & Biotechnology Companies
11.3.5.2.1.By Value (USD Million) 2024A-2034F
11.3.5.2.2. Market Share (%) 2024A-2034F
11.3.5.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.5.3. Food Businesses
11.3.5.3.1.By Value (USD Million) 2024A-2034F
11.3.5.3.2. Market Share (%) 2024A-2034F
11.3.5.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.5.4. Others
11.3.5.4.1.By Value (USD Million) 2024A-2034F
11.3.5.4.2. Market Share (%) 2024A-2034F
11.3.5.4.3. Y-o-Y Growth (%) 2024A-2034F
12.NORTH AMERICA HUMAN MICROBIOME MARKET SIZE & FORECAST 2024A-2034F
12.1.Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1.By Product
12.3.2. By Application
12.3.3. By Disease
12.3.4. By Type
12.3.5. By End-User
12.4. Country
12.4.1. United States
12.4.2. Canada
13.EUROPE HUMAN MICROBIOME MARKET SIZE & FORECAST 2024A-2034F
13.1.Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1.By Product
13.3.2. By Application
13.3.3. By Disease
13.3.4. By Type
13.3.5. By End-User
13.4.Country
13.4.1.Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14.ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE & FORECAST 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3.Market Segmentation
14.3.1.By Product
14.3.2. By Application
14.3.3. By Disease
14.3.4. By Type
14.3.5. By End-User
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4.Japan
14.4.5.Rest of APAC
15.MIDDLE EAST AND AFRICA HUMAN MICROBIOME MARKET SIZE & FORECAST 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1.By Product
15.3.2. By Application
15.3.3. By Disease
15.3.4. By Type
15.3.5. By End-User
15.4.Country
15.4.1.Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4.South Africa
15.4.5. Rest of Middle East and Africa
16. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE & FORECAST 2024A-2034F
16.1.Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1.By Product
16.3.2. By Application
16.3.3. By Disease
16.3.4. By Type
16.3.5. By End-User
16.4.Country
16.4.1.Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. COMPETITIVE LANDSCAPE
17.1.Company market share, 2021
17.2. Key player overview
17.3. Key stakeholders
18. COMPANY PROFILES
18.1. Vedanta Biosciences
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2.Key Clients
18.1.4.3.Market Share
18.1.4.4.Recent News & Development (Last 3 Yrs.)
18.2. Seres Therapeutics
18.3. Second Genome
18.4. Rebiotix
18.5. Microbiome Insights
18.6. 4D Pharma
18.7. Synlogic
18.8. Microbiome Therapeutics
18.9. AOBiome
18.10. uBiome
18.11.Finch Therapeutics
18.12. Seed Health
18.13. Viome
18.14. Holobiome
18.15. Axial Biotherapeutics
18.16. Other Prominent Players
19. APPENDIX
20.CONSULTANT RECOMMENDATION
1.1. Regional Market Share
1.2.Business Trends
1.3. Human Microbiome Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. RESEARCH METHODOLOGY
2.1.Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4.Primary Research
2.5.Secondary Research
2.5.1.Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. MARKET CHARACTERISTICS
3.1.Market Definition
3.2.Human Microbiome Market: COVID-19 Impact
3.3. Key Segmentations
3.4.Key Developments
3.5.Allied Industry Data
4.HUMAN MICROBIOME MARKET – INDUSTRY INSIGHTS
4.1. Industry Segmentation
4.2.COVID-19 overview of world economy
4.3.Industry Ecosystem Channel Analysis
4.4.Innovation & Sustainability
5. MACROECONOMIC INDICATORS
6. RECENT DEVELOPMENTS
7. MARKET DYNAMICS
7.1.Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4.Market Restraints
7.5. Market Trends
8.RISK ANALYSIS
9. MARKET ANALYSIS
9.1.Porter's Five Forces
9.2. PEST Analysis
9.2.1.Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10.HUMAN MICROBIOME MARKET
10.1.Overview
10.2. Historical Analysis (2018-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. HUMAN MICROBIOME MARKET SIZE & FORECAST 2024A-2034F
11.1. Overview
11.2.Key Findings
11.3.Market Segmentation
11.3.1.By Product
11.3.1.1. Drugs
11.3.1.1.1.By Value (USD Million) 2024A-2034F
11.3.1.1.2. Market Share (%) 2024A-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.1.2.Diagnostic Tests
11.3.1.2.1. By Value (USD Million) 2024A-2034F
11.3.1.2.2.Market Share (%) 2024A-2034F
11.3.1.2.3.Y-o-Y Growth (%) 2024A-2034F
11.3.1.3.Probiotics
11.3.1.3.1. By Value (USD Million) 2024A-2034F
11.3.1.3.2.Market Share (%) 2024A-2034F
11.3.1.3.3.Y-o-Y Growth (%) 2024A-2034F
11.3.1.4.Prebiotics
11.3.1.4.1. By Value (USD Million) 2024A-2034F
11.3.1.4.2.Market Share (%) 2024A-2034F
11.3.1.4.3.Y-o-Y Growth (%) 2024A-2034F
11.3.1.5.Others
11.3.1.5.1. By Value (USD Million) 2024A-2034F
11.3.1.5.2.Market Share (%) 2024A-2034F
11.3.1.5.3.Y-o-Y Growth (%) 2024A-2034F
11.3.2. By Application
11.3.2.1.Therapeutics
11.3.2.1.1. By Value (USD Million) 2024A-2034F
11.3.2.1.2.Market Share (%) 2024A-2034F
11.3.2.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.2.2. Diagnostics
11.3.2.2.1.By Value (USD Million) 2024A-2034F
11.3.2.2.2. Market Share (%) 2024A-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2.3. Others
11.3.2.3.1.By Value (USD Million) 2024A-2034F
11.3.2.3.2. Market Share (%) 2024A-2034F
11.3.2.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.By Disease
11.3.3.1.Infectious Disease
11.3.3.1.1. By Value (USD Million) 2024A-2034F
11.3.3.1.2.Market Share (%) 2024A-2034F
11.3.3.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.3.2. Gastrointestinal Disease
11.3.3.2.1.By Value (USD Million) 2024A-2034F
11.3.3.2.2. Market Share (%) 2024A-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.3. Endocrine & Metabolic Disorders
11.3.3.3.1.By Value (USD Million) 2024A-2034F
11.3.3.3.2. Market Share (%) 2024A-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.4. Cancer
11.3.3.4.1.By Value (USD Million) 2024A-2034F
11.3.3.4.2. Market Share (%) 2024A-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.5. Others Diseases
11.3.3.5.1.By Value (USD Million) 2024A-2034F
11.3.3.5.2. Market Share (%) 2024A-2034F
11.3.3.5.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.By Type
11.3.4.1.Fecal Microbiota Transplantation (FMT)
11.3.4.1.1. By Value (USD Million) 2024A-2034F
11.3.4.1.2.Market Share (%) 2024A-2034F
11.3.4.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.4.2. Peptide
11.3.4.2.1.By Value (USD Million) 2024A-2034F
11.3.4.2.2. Market Share (%) 2024A-2034F
11.3.4.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.3. Live Biotherapeutic Product
11.3.4.3.1.By Value (USD Million) 2024A-2034F
11.3.4.3.2. Market Share (%) 2024A-2034F
11.3.4.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.4.Others
11.3.4.4.1.By Value (USD Million) 2024A-2034F
11.3.4.4.2. Market Share (%) 2024A-2034F
11.3.4.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.5.By End-Users
11.3.5.1.Hospitals & Clinics
11.3.5.1.1. By Value (USD Million) 2024A-2034F
11.3.5.1.2.Market Share (%) 2024A-2034F
11.3.5.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.5.2. Pharmaceutical & Biotechnology Companies
11.3.5.2.1.By Value (USD Million) 2024A-2034F
11.3.5.2.2. Market Share (%) 2024A-2034F
11.3.5.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.5.3. Food Businesses
11.3.5.3.1.By Value (USD Million) 2024A-2034F
11.3.5.3.2. Market Share (%) 2024A-2034F
11.3.5.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.5.4. Others
11.3.5.4.1.By Value (USD Million) 2024A-2034F
11.3.5.4.2. Market Share (%) 2024A-2034F
11.3.5.4.3. Y-o-Y Growth (%) 2024A-2034F
12.NORTH AMERICA HUMAN MICROBIOME MARKET SIZE & FORECAST 2024A-2034F
12.1.Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1.By Product
12.3.2. By Application
12.3.3. By Disease
12.3.4. By Type
12.3.5. By End-User
12.4. Country
12.4.1. United States
12.4.2. Canada
13.EUROPE HUMAN MICROBIOME MARKET SIZE & FORECAST 2024A-2034F
13.1.Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1.By Product
13.3.2. By Application
13.3.3. By Disease
13.3.4. By Type
13.3.5. By End-User
13.4.Country
13.4.1.Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14.ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE & FORECAST 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3.Market Segmentation
14.3.1.By Product
14.3.2. By Application
14.3.3. By Disease
14.3.4. By Type
14.3.5. By End-User
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4.Japan
14.4.5.Rest of APAC
15.MIDDLE EAST AND AFRICA HUMAN MICROBIOME MARKET SIZE & FORECAST 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1.By Product
15.3.2. By Application
15.3.3. By Disease
15.3.4. By Type
15.3.5. By End-User
15.4.Country
15.4.1.Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4.South Africa
15.4.5. Rest of Middle East and Africa
16. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE & FORECAST 2024A-2034F
16.1.Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1.By Product
16.3.2. By Application
16.3.3. By Disease
16.3.4. By Type
16.3.5. By End-User
16.4.Country
16.4.1.Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. COMPETITIVE LANDSCAPE
17.1.Company market share, 2021
17.2. Key player overview
17.3. Key stakeholders
18. COMPANY PROFILES
18.1. Vedanta Biosciences
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2.Key Clients
18.1.4.3.Market Share
18.1.4.4.Recent News & Development (Last 3 Yrs.)
18.2. Seres Therapeutics
18.3. Second Genome
18.4. Rebiotix
18.5. Microbiome Insights
18.6. 4D Pharma
18.7. Synlogic
18.8. Microbiome Therapeutics
18.9. AOBiome
18.10. uBiome
18.11.Finch Therapeutics
18.12. Seed Health
18.13. Viome
18.14. Holobiome
18.15. Axial Biotherapeutics
18.16. Other Prominent Players
19. APPENDIX
20.CONSULTANT RECOMMENDATION
